Table 4

Association between clinical factors and in-hospital mortality of MFWR

ItemDeathAliveP value
Patients (n)176
Age (years)70.7±7.366.8±11.00.346
Female (%)35.333.31.000
Systolic BP (mm Hg)109.4±27.6102.2±21.60.572
Diastolic BP (mm Hg)71.7±20.064.3±11.30.406
Heart rate (beats per minute)82.6±20.586.3±20.50.704
SPO2 (%)86.4±11.386.3±12.60.997
Blood biochemistry
 CK (peak, u/L)2271.0±2677.61364.2±1616.50.452
 CKMB (peak, u/L)201.0±217.685.7±122.20.240
 RBC (×109/L)4.2±0.63.8±0.60.212
 PLT (×109/L)178.9±68.9185.3±21.00.826
  Creatine (µmol/L)86.8±25.892.8±24.40.638
 Early rupture (%)
Patency rate of IRA (%)
Ultrasonic cardiogram
  LVEDD (mm)54.2±3.354.5±9.30.953
  LVESD (mm)38.8±4.540.5±10.50.772
  EF (%)51.0±8.455.6±12.30.392
Hypertension (%)52.950.01.000
Diabetes (%)17.616.71.000
Cerebral infarction (%)
CKD (%)0.00.0
COPD (%)
  Anterior (%)53.333.3
  Inferior posterior (%)13.333.3
  High lateral (%)20.00.0
  Inferior and right ventricle (%)13.333.3
NSTEMI (%)11.850.00.089
IABP (%)5.916.70.462
Aspirin (%)
Clopidogrel (%)
Ticagrelor (%)
β-blocker (%)47.1100.00.048
ACEI/ARB (%)35.3100.00.014
CCB (%)
Statin (%)94.1100.01.000
  • Data are mean±SD and n (%).

  • ACEI/ARB, ACE inhibitors/angiotensin II receptor blockers; BP, blood pressure; CCB, calcium channel blocker; CK, creatine kinase; CKD, chronic kidney disease; CKMB, creatine kinase isoenzyme-B; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; IAPB, intra-aortic balloon pump; IRA, infarct-related artery; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; MFWR, myocardial free wall rupture; NSTEMI, non-ST segment elevated myocardial infarction; PLT, platelets; RBC, red blood cell; SPO2, oxyhemoglobin saturation by pulse oximetry; STEMI, ST segment elevated myocardial infarction.